mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 16, Issue 4, Pages 493-504
Publisher
Oxford University Press (OUP)
Online
2014-01-11
DOI
10.1093/neuonc/not242
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
- (2013) K. Tanaka et al. CLINICAL CANCER RESEARCH
- mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models
- (2013) D. Pachow et al. CLINICAL CANCER RESEARCH
- A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
- (2013) Andrea Lunardi et al. NATURE GENETICS
- Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients
- (2013) Matthieu Peyre et al. NEUROSURGERY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus
- (2012) Wei Li et al. EMBO REPORTS
- Long-term natural history of neurofibromatosis Type 2–associated intracranial tumors
- (2012) Michael S. Dirks et al. JOURNAL OF NEUROSURGERY
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
- (2012) M. F. James et al. MOLECULAR CANCER RESEARCH
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features
- (2012) S. Goutagny et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009
- (2012) T. A. Dolecek et al. NEURO-ONCOLOGY
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
- (2011) Jaishri O. Blakeley et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis
- (2011) David Neal Franz Expert Review of Anticancer Therapy
- Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2
- (2011) V.-F. Mautner et al. NEURO-ONCOLOGY
- The APL Paradigm and the “Co-Clinical Trial” Project
- (2011) Caterina Nardella et al. Cancer Discovery
- Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service
- (2010) D.G. Evans et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
- (2010) Calvin K. Yip et al. MOLECULAR CELL
- Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
- (2010) K D Hadfield et al. ONCOGENE
- Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2
- (2009) D. G. Evans et al. CLINICAL CANCER RESEARCH
- Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
- (2009) M. A. Lopez-Lago et al. MOLECULAR AND CELLULAR BIOLOGY
- NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
- (2009) M. F. James et al. MOLECULAR AND CELLULAR BIOLOGY
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
- (2009) Scott R. Plotkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Merlin and the ERM proteins – regulators of receptor distribution and signaling at the cell cortex
- (2009) Andrea I. McClatchey et al. TRENDS IN CELL BIOLOGY
- Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
- (2009) Nancy Lee et al. BMC Pharmacology & Toxicology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started